Celldex Therapeutics’ Post

🙌New publication from our group 👉Inhibitors of apoC3, TG levels, and risk of pancreatitis: a systematic review and meta-analysis ☝️The present updated meta-analysis of randomized clinical trials demonstrated that the utilization of apoC3 inhibitors in patients with hypertriglyceridemia correlated with reduced apoC3 and triglyceride levels, along with a decreased risk of acute pancreatitis compared to the placebo. https://lnkd.in/dPCJuWjq European Atherosclerosis Society walter masson Juan Patricio Nogueira Lorenzo Martin Lobo MD,MTSAC, FACC, FESC

This 6-month randomised controlled trial explored the effects of fenofibrate, a PPARα agonist, as adjunct therapy in mild-to-moderate ulcerative colitis. Combining fenofibrate with mesalamine significantly improved clinical outcomes, reducing inflammation markers like NLRP3 and faecal calprotectin while increasing SIRT1 and AMPK levels. Patients also reported enhanced quality of life through IBDQ scores. These findings highlight the potential of fenofibrate to modulate key inflammatory pathways, offering new hope for UC management. Access the full study and detailed slide decks on the #IMIDForum 🔗https://ow.ly/Z8Ux50UCBY1

(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.

Excellent talk by Dr. Claire Harrison on targeted therapy in PV and how to clinically handle ET heterogeneity. She discussed the importance of properly defining what a true therapeutic molecular response is and carefully deciding which patients need to be treated. #ESHMPN2024

🚨 We are excited to share that the first patient has been enrolled in an investigator-sponsored phase 2 clinical trial of vidofludimus calcium for post-COVID syndrome, sponsored by Goethe University Frankfurt and funded by a German government grant. 💊 We are proud to provide the study drug, vidofludimus calcium, which is being tested not only for its potential to alleviate severe post-COVID fatigue but also for its ability to suppress Epstein-Barr virus reactivation - a suspected cause of this fatigue.  🧠 This study could also have a potential read-through to our multiple sclerosis development program. MS patients suffer from similar debilitating fatigue symptoms, for which currently no effective therapies are available. 💪 ➡️ Learn more: https://bit.ly/4gfmgkX Universitätsmedizin Frankfurt #Immunic #IMUX #vidofludimus #IMU838 #PostCOVID #PCS #fatigue #EpsteinBarr #EBV #MultipleSclerosis #MS #MSResearch #ClinicalTrials

OS Therapies announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary #Endpoint with Statistical Significance in the #Prevention of Recurrent, Fully Resected, #Lung #Metastatic #Osteosarcoma #ostherapies #ostx https://lnkd.in/eKjequuB

⭐ On the Influence of Patient-Specific Airways on In-Silico Assessment of Drug Delivery in COPD Patients. Presented last week at #DDL2024, this study underscores the value of accounting for inter-patient variability using patient-specific in-silico models. By doing so, researchers can enhance the precision of lung drug deposition studies, paving the way for more effective, individualized therapies. 👏 Big congratulations to our team: Navid M., Hosein SADAFI, and Jan De Backer. #DrugDelivery #FRI #LungHealth

💡 2024 paper by Shou-Wu Lee et al. on the impact of sequential therapies after first-line systemic therapies in unresectable HCC. The study found that the patients who were able to undergo sequential therapy had a better survival outcome compared to those who received only one agent. Further analysis found patients who received sequential systemic therapy had significantly better ALBI level at baseline. Thus, the ALBI level might be regarded as a tool to assess survival outcomes before the initiation of systemic first-line therapy. Access the complete paper👇 https://ow.ly/XxBa50RFtLX #MedEd #HCC #IO

📑 EANO European Association of Neuro-Oncology Guideline on molecular testing for Meningiomas for targeted therapy selection. 🧬 Meningiomas can express a wide range of molecular alterations and markers including  NF2, AKT1, SMO, SMARCE1, PIK3CA, CDKN2A/B, CDK4/6, TERT, TRAF7, BAP1, KLF4, ARID1/2, SUFU, PD-L1, SSTR2A, PR/ER, mTOR, VEGFR, PDGFR, as well as homologous recombination deficiency (HRD), genomic copy number variations, DNA methylation classes and combined gene expression profiles. 🎯 Based on the established ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets) evidence level criteria, unfortunately, no molecular target reached ESCAT I (“ready for clinical use”) classification and only mTOR pathway activation and NF2 alterations reached ESCAT II (“investigational”) classification, respectively. 💡 This highlights the need for future research and innovative trial design that incorporates molecular profiling that allows for the evaluation of targeted therapy in these tumors. #neuronc #medonc #meningiomas #eano #targeted #therapy #molecular #profiling #personalized #medicine

Randomized clinical trial show that DPYD/UGT1A1 pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan reduced the risk of toxicity by 90% https://buff.ly/4fbiZRU